References:
Ando M et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 2012;69(2):457-65. Abstract
Aogi K et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: Efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011;129(3):829-38. Abstract
Dedes KJ et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Eur J Cancer 2009;45(8):1397-406. Abstract
Gradishar WJ et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27(22):3611-9. Abstract
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Gray R et al. Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27(30):4966-72. Abstract
Lee F et al. Synergistic activity of ixabepilone plus other anticancer agents: Preclinical and clinical evidence. Ther Adv Med Oncol 2011;3(1):11-25. Abstract
Li T et al. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: An Eastern Cooperative Oncology Group study (E1103). Breast Cancer Res Treat 2012;[Epub ahead of print]. Abstract
Link JS. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007;7(10):779-83. Abstract
Moreno-Aspitia A et al. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009;31(8):1619-40. Abstract
National Comprehensive Cancer Network (NCCN®). NCCN clinical practice guidelines in oncology. Breast Cancer — Version 1.2012. Available at: www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Nelli F et al. Gemcitabine and carboplatin for pretreated metastatic breast cancer: The predictive value of immunohistochemically defined subtypes. Int J Clin Oncol 2012;[Epub ahead of print]. Abstract
Rak Tkaczuk KH. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. Breast Cancer (Auckl) 2011;5:1-14. Abstract
Schneider BP et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8. Abstract
Telli ML et al. First-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 2009;9(Suppl 2):66-72. Abstract